Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug23 | 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse Wiki | 0.38 |
| drug1119 | CytoSorb-Therapy Wiki | 0.38 |
| drug651 | Brief Skills for Safer Living Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013405 | Suicide NIH | 0.27 |
| D059020 | Suicidal Ideation NIH | 0.27 |
| D008269 | Macular Edema NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011111 | Polymyalgia Rheumatica NIH | 0.22 |
| D013700 | Giant Cell Arteritis NIH | 0.22 |
| D000163 | Acquired Immunodeficiency Syndrome NIH | 0.19 |
| D003863 | Depression, NIH | 0.17 |
| D019052 | Depression, Postpartum NIH | 0.13 |
| D002908 | Chronic Disease NIH | 0.10 |
| D015658 | HIV Infections NIH | 0.09 |
| D009103 | Multiple Sclerosis NIH | 0.09 |
| D003866 | Depressive Disorder NIH | 0.07 |
| D013315 | Stress, Psychological NIH | 0.07 |
| D007239 | Infection NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011505 | Cystoid macular edema HPO | 0.22 |
| HP:0000716 | Depressivity HPO | 0.07 |
Navigate: Correlations HPO
There are 7 clinical trials
The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.
Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)
Measure: % adherence to each pharmacological class Time: during the period from 20 April 2020 to 7 May 2020Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)
Measure: number of occurrence of medical events at 1 year Time: throughout the study for 12 monthsDescription: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change
Measure: Expressed in %: Non-pharmacological treatment/lifestyle: Time: during the period from 20 April 2020 to 7 May 2020Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire.
An increased proportion of deaths occur in the intensive care unit (ICU). Some amenable factors such as end-of-life practices may contribute to complicated grief. Because of the COVID-19 pandemic, visitor restrictions in health care facilities have been implemented. Families were also unable to implement usual funerals. The investigators hypothesize that these policies and practices may impact grief during covid-19 pandemic. The aim of this study is to evaluate the prevalence of complicated grief after death of a relative in the ICU during the COVID-19 pandemic.
Description: Proportion of complicated grief 4 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. The primary outcome measure is the Inventory of Complicate Grief (ICG) score. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score > 25 indicate complicated grief. All patients who died in ICU after SARS-Cov-2 infection will be identify. Their relatives (spouse, children and relative who served as a surrogate) will also be identify. Relatives will be included up to 4 months after the time of death.
Measure: Proportion of complicated grief 4 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. Time: 4 months after relative deathDescription: Proportion of complicated grief 6 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. The primary outcome measure is the Inventory of Complicate Grief (ICG) score. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score > 25 indicate complicated grief. All patients who died in ICU after SARS-Cov-2 infection will be identify. Their relatives (spouse, children and relative who served as a surrogate) will also be identify. Relatives will be included up to 6 months after the time of death.
Measure: Proportion of complicated grief 6 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. Time: 6 months after relative covid-19 deathDescription: Proportion of complicated grief 12 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. The primary outcome measure is the Inventory of Complicate Grief (ICG) score. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score > 25 indicate complicated grief. All patients who died in ICU after SARS-Cov-2 infection will be identify. Their relatives (spouse, children and relative who served as a surrogate) will also be identify. Relatives will be included up to 12 months after the time of death.
Measure: Proportion of complicated grief 12 month after death in relative from patients who died in ICU after covid-19 infection evaluate with ICG score. Time: 12 months after relative covid-19 deathSince December 2019, China and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called SARS-CoV-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which is called Covid-19 (Coronavirus Disease 2019). It is estimated that around 20% of symptomatic patients will be severe enough to warrant hospitalization, of which around 5% will be in intensive care. Organ damage is multiple in Covid infection: respiratory, digestive, renal, neurological, cardiovascular due to the infection or its care. There is also a psychological and social impact of the infection or of the care that should be measured. In this context, investigator will assess the physical and psychological complaints of patients who have presented a severe form of SARS-CoV-2 infection. The final objective being to identify the needs to offer follow-up adapted to this emerging pathology.
Description: the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Modified Medical Research Council"
Measure: Identify functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Medical Outcome Study Short Form 36 (MOS SF-36)"
Measure: Identify functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by FRIED criteria
Measure: Identify functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)"
Measure: Identify functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: complaints will be assessed by questionnaire "Modified Medical Research Council"
Measure: description of functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: complaints will be assessed by questionnaire "Medical Outcome Study Short Form 36 (MOS SF-36)"
Measure: description of functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: complaints will be assessed by FRIED criteria
Measure: description of functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: complaints will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)"
Measure: description of functionnal and psychosocial complaints Time: 3 months after last hospitalizationDescription: Risk factors are defined according to age, concomitant treatment, comorbidities before hospitalization
Measure: Identify the factors favoring the persistence of complaints Time: 3 months after last hospitalizationDescription: Complaints will be assessed by questionnaire"Modified Medical Research Council"
Measure: Describe functional, neuropsychological and social complaints at a distance Time: 3 months after last hospitalizationDescription: Complaints will be assessed by questionnaire"Medical Outcome Study Short Form 36 (MOS SF-36)"
Measure: Describe functional, neuropsychological and social complaints at a distance Time: 3 months after last hospitalizationDescription: Complaints will be assessed by FRIED criteria
Measure: Describe functional, neuropsychological and social complaints at a distance Time: 3 months after last hospitalizationDescription: Complaints will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)"
Measure: Describe functional, neuropsychological and social complaints at a distance Time: 3 months after last hospitalizationDescription: Medical and surgical consultations after discharge will be measured as percentage
Measure: Describe the needs for medical and surgical consultations after discharge from hospital Time: 3 months after last hospitalizationDescription: neuropsychological support, dietetics, social assistance after discharge will be measured as percentage
Measure: Describe the needs for neuropsychological support, dietetics, social assistance after discharge from hospital. Time: 3 months after last hospitalizationDescription: Describe the factors of inequalities in access to care and study their impact on the occurrence of a SARS-CoV-2 infection, its severity and the occurrence of a functional or psycho-social complaint.
Measure: Describe the factors of inequalities in access to care Time: 3 months after last hospitalizationREMPAR EHPAD study addresses environmental and managerial factors associated with an outbreak of COVID 19 in French Long Term Care Institutions in the spring of 2020. The survey used a mixed methodology, combining qualitative and quantitative approaches, with a questionnaire send to all identified institutions (n=501) and qualitative interviews with facility directors (n=21).
Description: Number of case (confirmed or probable) of COVID 19 in each facility
Measure: case of COVID 19 Time: 01 september 2020, survey closing dateThe non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.
Description: Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at inclusion in the study
Measure: Prevalence of SARS CoV2 infection in PVVIH in Hauts de France Time: InclusionDescription: Determination of the number of patients with microbiologically or clinically-biologically proven SARS CoV2 infection at the end of the study
Measure: Prevalence of SARS CoV2 infection in PVVIH in Hauts de France Time: through study completion, an average of 19 monthsDescription: Percentage of patients who stopped their antiretroviral treatment
Measure: Determine the incidence rate of COVID 19 among PVVIH antiretroviral treatment Time: through study completion, an average of 19 monthsDescription: Reason for discontinuing antiretroviral treatment
Measure: Determine the incidence rate of COVID 19 among PVVIH discontinuing antiretroviral treatment Time: through study completion, an average of 19 monthsDescription: Percentage of patients who stopped all follow-up by an infectious disease specialist
Measure: Determine the incidence rate of COVID 19 among PVVIH who stopped all follow-up Time: through study completion, an average of 19 monthsDescription: Evaluation of the psychological scales HAD on PVVIH
Measure: Psychological consequences of this epidemic among PVVIH : HAD Time: through study completion, an average of 19 monthsDescription: Evaluation of the psychological scales PROQOL-HIV on PVVIH
Measure: Psychological consequences of this epidemic among PVVIH : PROQOL-HIV Time: through study completion, an average of 19 monthsThe purpose of this case-control study is to assess the association of the current and former consumption of tobacco and nicotine in the risk of acquisition of severe acute respiratory syndrome 2 (SARS-CoV-2). the investigators will send a structured interview by mail regarding use of tobacco and nicotine to 1000 healthcare workers (500 cases with a positive Real Time Polymorphism Chain Reaction (RT-PCR) and 500 controls with a negative PCR) who were tested in Paris for in March, 2020. OR will be estimated by conditional logistic regression modelling with matching for sex and age.
Description: No intervention
Measure: questionnaire to assess strength of correlation between current smoking and SARS-CoV-2 RT-PCR positivity Time: 30 minutesDescription: No intervention
Measure: questionnaire to assess strength of correlation between current alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity Time: 30 minutesDescription: No intervention
Measure: questionnaire to assess strength of correlation between former smokers and SARS-CoV-2 RT-PCR positivity Time: 30 minutesDescription: No intervention
Measure: questionnaire to assess strength of correlation between former alternative nicotine delivery systems and SARS-CoV-2 RT-PCR positivity Time: 30 minutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports